What side effects can patients expect from Padcev (enfortumab vedotin)?
Padcev (enfortumab vedotin-ejfv) can cause a range of side effects, including reactions tied to both the drug’s anticancer effects and its delivery as an antibody-drug conjugate. Commonly reported effects include skin reactions, nerve problems, fatigue, and blood sugar changes (hyperglycemia) in some patients.[1]
What are the most common side effects?
The most commonly reported side effects for Padcev include:
- Fatigue
- Decreased appetite
- Nausea and constipation
- Rash and other skin reactions
- Peripheral neuropathy (nerve pain, numbness, tingling)
- Hyperglycemia (high blood sugar)[1]
What serious side effects should patients watch for?
Some patients can experience more serious or treatment-limiting toxicities. Safety information for Padcev includes risks such as:
- Severe skin reactions
- Significant peripheral neuropathy
- Immune-related or lung-related complications (pneumonitis can occur)
- Serious hyperglycemia or diabetic complications in susceptible patients[1]
How do side effects compare across cancers/lines of therapy?
The safety profile is generally similar across clinical settings where Padcev is used, but the chances of particular side effects can vary based on:
- Combination partners (for example, if Padcev is given with other anticancer drugs)
- Patient baseline conditions (such as pre-existing neuropathy or diabetes)
- Treatment duration and dose reductions or interruptions[1]
What can patients do to manage side effects?
Clinicians often manage side effects by:
- Monitoring and treating blood sugar abnormalities during therapy
- Adjusting dose or pausing treatment if neuropathy or skin reactions worsen
- Using supportive medications for nausea and constipation
- Checking early for lung symptoms and escalating care if pneumonitis is suspected[1]
Where can I check the most up-to-date safety information?
For the latest prescribing information and labeled adverse reactions, DrugPatentWatch.com links to Padcev’s drug details and related documentation, which can help confirm current safety statements.[1]
Sources:
[1] https://www.drugpatentwatch.com/padcev